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Fumarate induces redox-dependent senescence
by modifying glutathione metabolism
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Mutations in the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) are
associated with a highly malignant form of renal cancer. We combined analytical chemistry
and metabolic computational modelling to investigate the metabolic implications of FH loss in
immortalized and primary mouse kidney cells. Here, we show that the accumulation of
fumarate caused by the inactivation of FH leads to oxidative stress that is mediated by the
formation of succinicGSH, a covalent adduct between fumarate and glutathione. Chronic
succination of GSH, caused by the loss of FH, or by exogenous fumarate, leads to persistent
oxidative stress and cellular senescence in vitro and in vivo. Importantly, the ablation of p21, a
key mediator of senescence, in Fh1-deﬁcient mice resulted in the transformation of benign
renal cysts into a hyperplastic lesion, suggesting that fumarate-induced senescence needs to
be bypassed for the initiation of renal cancers.
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F
umarate hydratase (FH) mediates the reversible conversion
of fumarate to malate in the tricarboxylic acid (TCA) cycle.
The biallelic inactivation of FH leads to hereditary
leiomyomatosis and renal cell cancer (HLRCC), a hereditary
cancer syndrome characterized by the presence of benign
tumours of the skin and uterus, and a highly malignant form of
renal cell cancer1. Fumarate, which is highly accumulated in FH-
deﬁcient cells, has long been considered a major pro-oncogenic
factor for HLRCC tumorigenesis2. It was initially proposed that
the stabilization of the hypoxia-inducible factors (HIFs), caused
by the fumarate-dependent inhibition of prolyl hydroxylases, was
instrumental for tumour formation3,4. However, the recent
ﬁndings that the genetic deletion of HIFs does not prevent cyst
formation in Fh1-deﬁcient mice5 challenged their aetiological role
in these tumours, indicating that other HIF-independent
oncogenic pathways are involved.
Fumarate is a moderately reactive a,b-unsaturated electrophilic
metabolite that can covalently bind to cysteine residues of
proteins under physiological conditions. This process, called
protein succination, is a feature of FH-deﬁcient tumour tissues,
where fumarate accumulates to millimolar levels6. Keap1, an E3
ubiquitin ligase and an inhibitor of the transcription factor
nuclear erythroid-related factor 2 (NRF2), has recently been
identiﬁed as a target of protein succination and consequent
inactivation, which led to the induction of NRF2 and a potent
antioxidant response5,7. Of note, among the most characterized
targets of NRF2, haem oxygenase 1 (HMOX1) has been found to
be synthetic lethal with FH8 suggesting that the activation of
NRF2 and its downstream targets might have an important
prosurvival role in Fh1-deﬁcient cancer cells, beyond the control
of redox homeostasis.
Although Keap1 succination could explain the antioxidant
transcriptional signature in FH-deﬁcient tissues, other direct
oxidation mechanisms could contribute to such a response. In
fact, the loss of FH has been previously associated with the
increased production of reactive oxygen species (ROS)9, and the
accumulation of fumarate in FH-deﬁcient cancer cell lines leads to
the formation of an adduct between fumarate and glutathione
(GSH), which depletes intracellular NADPH and enhances
oxidative stress10. Nevertheless, a comprehensive investigation of
the mechanism by which FH loss triggers oxidative stress, and the
biological consequences of such stress, have not been performed.
Systems biology has become an invaluable tool for investigating
cellular metabolism as it allows integrating data from different
platforms such as transcriptomics and metabolomics. This
approach was recently used to identify the molecular determi-
nants of the Warburg effect11 and to explore novel therapeutic
strategies for cancer such as metabolic synthetic lethality12. In the
present work, we used a combination of computational biology,
metabolomics and mouse genetics to investigate the overall
metabolic effects of FH loss and, in particular, the possible
outcomes of FH loss and oxidative stress. We demonstrated that
the accumulated fumarate leads to oxidative stress by covalently
binding to reduced GSH in a non-enzymatic reaction that forms
succinicGSH. We also demonstrated that the oxidative stress
induced by GSH succination is necessary and sufﬁcient to elicit
cellular senescence in non-transformed cells and that the ablation
of senescence can initiate a tumorigenic programme in the
kidneys of Fh1-deﬁcient mice.
Results
Oxidative stress in FH-deﬁcient cells. To elucidate the metabolic
changes that occur on the loss of FH, we utilized the previously
characterized mouse FH-deﬁcient kidney cells (Fh1D/D) and their
wild-type (wt) isogenic control (Fh1ﬂ/ﬂ) (ref. 8). Initially, we
found that genes whose expression is upregulated in FH-deﬁcient
cells8 are signiﬁcantly enriched with oxidative stress
genes (hypergeometric P value of 5.505e 04, see Methods).
Reassuringly, genes that are upregulated in HLRCC clinical
samples relative to normal kidney tissues7 are also signiﬁcantly
enriched with oxidative stress genes (hypergeometric P value of
3.984e 06). The genes that featured most highly (Fig. 1a) were
then validated by quantitative PCR (qPCR; Fig. 1b). In line with
this oxidative stress signature, Fh1-deﬁcient cells exhibit
increased ROS production and a substantial drop in GSH/GSSG
ratio (Fig. 1c,d).
To better understand the metabolic consequences of FH loss,
we performed a comprehensive analysis of extracellular metabo-
lite exchange rates using liquid chromatography-mass spectro-
metry (LC-MS; Supplementary Table 1). We then generated in
silico genome-scale metabolic models of the FH-deﬁcient and wt
cells by incorporating the gene expression and metabolite
exchange rates measured in these cell lines within a generic
metabolic model13 (see Methods). Of note, these implemented
models not only explore essential reactions for biomass
production, as previously done8, but also allowed us to predict
changes in metabolic ﬂuxes on loss of FH. We ﬁrst examined the
models by testing their ability to predict the measured ﬂux rates
via cross-validation (leaving one out). For each iteration, we
regenerated a new model based on the gene expression and a
partial set of the metabolite uptake and secretion rates and used
these models to predict the ﬂux rate through the reaction whose
ﬂux measurement was omitted. Signiﬁcant correlation was found
between the measured and predicted ﬂux rates (R¼ 0.617 and
0.551, P values of 6.59e 04, and 2.63e 03, when testing the wt
and FH-deﬁcient models, respectively Supplementary Table 2).
Following the validation of the models, we utilized them to
systematically explore the metabolic differences between the FH-
deﬁcient and control cells. We computed the capacity of the two
models to produce each of the 1,491 metabolites included in the
models. The FH-deﬁcient model was found to have a higher
capacity to produce 43 metabolites. Among the top ones are four
derivatives of GSH (Supplementary Fig. 1a,b). Furthermore, GSH
biosynthesis was projected to be an essential metabolic reaction in
the Fh1-deﬁcient model (Supplementary Fig. 3b). We also
predicted that the FH-deﬁcient model has a signiﬁcantly lower
capacity to produce reducing power, in the form of NADH and
NADPH, compared with the wt model (Supplementary Fig. 1c).
Of note, in the computational model, the loss of HMOX1, whose
essentiality in the Fh1-deﬁcient cells has been previously shown8,
was expected to exacerbate the decreased ability of the FH-
deﬁcient cells to produce NADPH.
Metabolomics revealed GSH succination in FH-deﬁcient cells.
To further conﬁrm that GSH metabolism was altered in FH-
deﬁcient cells an LC-MS analysis of steady-state intracellular
metabolites was performed. Among the most signiﬁcant meta-
bolites accumulated in FH-deﬁcient cells a putative GSH adduct
was detected (annotated by Metlin database as the formate adduct
of pyruvilGSH; Fig. 2a). Since this metabolite is speciﬁc to FH-
deﬁcient cells and is poorly characterized, we decided to elucidate
its structure by LC-MS/MS and NMR analyses. The MS/MS
fragmentation pattern and the presence of fumarate and GSH
fragments as diagnostic daughter ions (Fig. 2b), strongly indicated
that this metabolite was wrongly annotated and is instead an
adduct of fumarate binding to GSH, which we deﬁned as succi-
nicGSH (Supplementary Fig. 2a for the chemical structure).
Furthermore, NMR pulse-ﬁeld gradient correlation spectroscopy
(pfgCOSY), pulse-ﬁeld gradient total correlation spectroscopy
(pfgTOCSY; Supplementary Fig. 2b) and further LC-MS/MS
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analysis (Supplementary Fig. 2c) conﬁrmed the chemical struc-
ture of this molecule (registered as S-(1,2-Dicarboxyethyl)
glutathione: CAS Registry Number [1115-52-2]).
After elucidating the molecular structure of succinicGSH, we
conﬁrmed its presence in Fh1D/D cells using targeted LC-MS,
showing that succinicGSH represents about 10% of the total GSH
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Figure 1 | Antioxidant signature in FH-deﬁcient cells. (a,b) Expression of genes that belong to ‘antioxidant response’ retrieved from a gene expression
array (a) and validated by qPCR (b) from FH-deﬁcient mouse kidney epithelial, as compared with control cells. qPCR data were obtained from three
independent cultures and represented as average±s.e.m. (c,d) FH-deﬁcient cells exhibit increased oxidative stress measured by mitosox (c), DCFDA (c)
and by decreased GSH/GSSG ratio (d). Results were obtained from three independent experiments and represented as average±s.e.m.
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Figure 2 | Accumulation of fumarate leads to GSH succination. (a) Relative abundance of intracellular metabolites in FH-deﬁcient cells measured by LC-
MS. Results were obtained from nine independent cultures. (b) Fragmentation pattern of the metabolite annotated as pyruvilGSH obtained by LC-MS/MS.
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in these cells (Fig. 2c,d). It is noteworthy that succinicGSH was
also recently characterized in the human FH-deﬁcient renal
cancer cell line UOK262 (ref. 10) and we conﬁrmed its presence
in these cells (Fig. 2e).
SuccinicGSH is formed by a reaction of fumarate with GSH. To
further elaborate on the source of succinicGSH in FH-deﬁcient
cells, we tested the hypothesis that this compound is formed
by a reaction between accumulated fumarate and GSH. To this
end, FH-deﬁcient cells were incubated with uniformly labelled
13C5-glutamine, which generates 13C5-labelled glutamate and
13C4-labelled fumarate, and the isotopologue distribution of
succinicGSH was analysed by LC-MS (see Fig. 3a for a schematic
diagram of the reactions). SuccinicGSH isotopologues were
consistent with carbons coming mostly from fumarate (mþ 4)
and glutamate (mþ 5), which eventually gave rise to a
mþ 9-labelled metabolite (Fig. 3b).
At physiological pH, the thiol residue of GSH is scarcely
deprotonated (pKa¼ 9.2). Therefore, the reactions between GSH
and electrophilic molecules are generally catalysed by enzymes,
such as GSH transferases, which activate GSH by ionizing its thiol
group (SH) into the more reactive thiolate (S ) residue14. We
therefore wanted to address whether the production of
succinicGSH required an enzymatic reaction. To this end, GSH
and fumarate, at a concentration found in Fh1-deﬁcient cells15,
were mixed in a physiological buffer. To avoid interference from
endogenous fumarate and succinicGSH from cell extracts, 13C2-
fumarate was used. When labelled fumarate and GSH were mixed
in a physiological buffer, a signiﬁcant amount of mþ 2 labelled
succinicGSH was detected (Fig. 3c). The addition of cell protein
extracts from Fh1-deﬁcient cells did not increase and, heat
inactivation did not decrease the production of succinicGSH,
indicating that the formation of the compound under these
conditions is non-enzymatic. Together these results demonstrated
that fumarate, when accumulated, leads to GSH succination.
We further investigated the rate of succinicGSH formation and
its degradation. To this aim, Fh1-deﬁcient cells were incubated
with 13C5-glutamine and the kinetics of succinicGSH formation
was monitored. The labelling of succinicGSH occurred very
rapidly on incubation with labelled glutamine and it tailed GSH
biosynthesis (Fig. 3d). Of note, we could not detect the succinated
form of the GSH precursor g-glutamylcysteine in Fh1-deﬁcient
cells, suggesting that GSH, rather than one of its precursors, is
subject to succination. We ﬁnally investigated the fate of
succinicGSH. Experiments on Fh1-deﬁcient cells incubated with
13C5-glutamine revealed that succinicGSH is excreted in the
media (Fig. 3e) and its isotopologue labelling matches that of
intracellular succinicGSH (Fig. 3b). Importantly, in these cells, we
have also identiﬁed a succinated form of the dipeptide cys–gly,
the degradation product of GSH. The rate of production of this
metabolite, which followed both GSH and succinicGSH kinetics
(Fig. 3f), suggests that succinic cys–gly is likely a breakdown
product of succinicGSH. Together this investigation revealed that
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succinicGSH is formed by succination of newly synthesized GSH
and that this metabolite is partly degraded into succinated cys–gly
and partly secreted to the media (See Fig. 3a for a schematic of
these reactions).
Succination of GSH increases oxidative stress. We wanted to
investigate the link between GSH succination and the oxidative
stress signature that characterize FH-deﬁcient cells (Fig. 1). Sul-
livan et al.10 previously proposed that enhanced oxidative stress
in these cells is caused by the NADPH-depleting conversion of
succinicGSH into GSH, a reaction catalysed by GSH reductase
(GR). However, this conclusion was based on indirect evidence,
that is, consumption of NADPH on incubation of a methylated
version of succinicGSH at high concentration and GR10. To test
their hypothesis, we measured the activity of GR towards
chemically synthesized succinicGSH as compared to its natural
substrate oxidized GSH (GSSG) by measuring the products.
While GSSG was quickly reduced to GSH, we could not detect
GSH production from succinicGSH in the presence of GR
(Supplementary Fig. 3a). Therefore, it is unlikely that the
detoxiﬁcation of succinicGSH by GR provides explanation for
the enhanced redox stress in Fh1-deﬁcient cells. Several other
factors could contribute to the oxidative stress in these cells,
including electron transport chain dysfunction, as previously
documented16. Therefore, to investigate the mechanistic link
between fumarate accumulation, succination of GSH, and
oxidative stress, respiration-competent Fh1ﬂ/ﬂ cells were
incubated with a cell-permeable derivative of fumarate, dimethyl-
fumarate (DMF). DMF quickly reacted with intracellular GSH
leading to the formation of dimethyl-succinicGSH (Fig. 4a).
Of note, the incubation with DMF caused a dose-dependent
depletion of GSH (Fig. 4b), a substantial drop in the GSH/GSSG
ratio (Fig. 4c) and increased oxidative stress (Fig. 4d,e).
Furthermore, DMF treatment elicited an antioxidant gene
response similar to that observed in Fh1D/D cells (Fig. 4f).
Importantly, the incubation with a cell-permeable derivative of
GSH, ethyl-GSH, signiﬁcantly decreased the ROS production
triggered by DMF (Fig. 4e). Together these results indicate that
the succination of GSH, but not its detoxiﬁcation, is responsible
for the oxidative stress observed in Fh1-deﬁcient cells
GSH succination increases GSH biosynthesis. We hypothesized
that the chronic depletion of GSH caused by succination could
perturb cell metabolism and contribute to a general deregulation
of redox homeostasis. To address this question, we reconstructed
the metabolic models previously generated to include GSH suc-
cination. Of note, the inclusion of this reaction improved the
ability of the FH-deﬁcient model to predict the measured ﬂux
rates (R¼ 0.570, P¼ 1.81E 03; Supplementary Table 2). We
found that in the FH-deﬁcient model, but not in the wt model,
GSH succination signiﬁcantly reshaped the generation of redu-
cing power (Supplementary Fig. 1b). Furthermore, the model
revealed that GSH succination impinged GSH metabolism and
cystine uptake (Supplementary Table 3). Notably, the selective
uptake of cystine (an oxidized dimer of cysteine), rather than
methionine, as a precursor for cysteine and subsequently GSH
biosynthesis imposes a further metabolic constraint: the reduction
of cystine to cysteine requires NADPH, the supply of which
becomes critical for GSH biosynthesis (see Supplementary
Fig. 3b). In line with these predictions, Fh1D/D cells exhibited a
signiﬁcant overexpression of Slc7a11, a member of the cystine
transporter xCT, which was functionally associated with
increased uptake of cystine (Fig. 5a,b). The rate-limiting step in
GSH biosynthesis is the synthesis of g-glutamylcysteine
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from glutamate and cysteine by g-glutamylcysteine synthetase
(GCL; see Fig. 3a for a schematic representation of these reac-
tions). GSH is then synthesized by GSH synthetase (GSS), which
adds glycine to g-glutamylcysteine. Therefore, the GSH bio-
synthesis rate could be assessed by the rate of incorporation of
glutamine-derived glutamate after incubation with 13C5-gluta-
mine. The incorporation of glutamate into GSH was faster in FH-
deﬁcient cells, meaning that, as predicted by the computational
models, GSH production is accelerated in FH-deﬁcient cells
(Fig. 5c). Moreover, the increased biosynthesis rate of GSH
caused by GSH succination led to a larger steady-state pool of
GSH (Fig. 5d). In line with these ﬁndings, genes encoding for
cystine transport (Slc7a11) and enzymes of the GSH biosynthetic
pathway (GSS and GCL), are signiﬁcantly upregulated in HLRCC
patients (Supplementary Fig. 4)7,17. All in all, these suggest that
increased GSH biosynthesis could be a compensatory mechanism
that mitigates the increased oxidative stress in FH-deﬁcient cells.
To test whether GSH biosynthesis is required for the survival of
FH-deﬁcient cells, we inhibited cystine uptake using a well-
characterized xCT inhibitor, sulfasalazine. Reassuringly, the
inhibition of cystine uptake signiﬁcantly impaired GSH biosynth-
esis in both genotypes (Fig. 5e). However, only Fh1D/D cells were
negatively affected by the drug (Fig. 5f). Since GSH biosynthesis
requires NADPH supply to reduce cystine to cysteine
(Supplementary Fig. 3b), we tested the effects of inhibiting
NAPDH production on the survival of FH-deﬁcient cells. The
pentose phosphate pathway (PPP) is the major supply of NADPH
in cells and so cells were incubated with 6-amino nicotinamide, a
known inhibitor of the PPP enzyme 6-phosphogluconate
dehydrogenase. 6-Amino nicotinamide effectively halted PPP
activity in both genotypes (Fig. 5g) but it only affected the
survival of FH-deﬁcient cells (Fig. 5h). In summary, these results
indicate that GSH biosynthesis is essential for FH-deﬁcient cells
to overcome the oxidative stress caused by GSH succination.
Loss of FH leads to oxidative stress-mediated senescence. We
hypothesized that the observed metabolic reprogramming is a
required step for the support of cell transformation. Since both
the human and mouse FH-deﬁcient cells used here were
immortalized cell lines, we tested the effects of GSH succination
on primary kidney cells isolated from Fh1ﬂ/ﬂ mouse pups and on
the human diploid ﬁbroblasts IMR90. On infection with adeno-
viral vector expressing Cre recombinase (Ad-Cre), Fh1ﬂ/ﬂ cells,
which lost FH activity, underwent proliferation arrest, whereas
the uninfected cells continued to proliferate (Fig. 6a). The pro-
liferation arrest was associated with a robust induction of the
cyclin-dependent kinase inhibitor p21CIP1/WAF1 (thereafter
referred to as p21) and of the cyclin-dependent kinase inhibitor
2A p16 (Fig. 6b). These results suggested that oxidative stress-
mediated cellular senescence18 might be responsible for the
observed phenotype. Similarly, the non-transformed non-
immortalized human diploid ﬁbroblast cells IMR90 exhibited a
signiﬁcant upregulation of p21 on acute depletion of FH (Fig. 6c).
To conﬁrm the involvement of senescence, we tested the
senescence-associated b-galactosidase (SA-b-gal) activity in FH-
deﬁcient cells. On infection with Ad-Cre, Fh1ﬂ/ﬂ exhibited a
strong SA-b-gal staining (Fig. 6d and Supplementary Fig. 5a).
Reassuringly, the loss of FH was also associated with the
activation of an antioxidant response similar to that observed in
Fh1-deﬁcient cell lines (Supplementary Fig 5b). To ascertain the
role of oxidative stress in senescence induction, cells were
incubated with ascorbate (vitamin C) or Trolox (vitamin E
derivative), two well-characterized antioxidants, which are water
or lipid soluble respectively. Importantly, both the growth
inhibitory effect, and the induction of SA-b-gal activity in Fh1-
deﬁcient primary kidney cells were abrogated by these
antioxidants (Fig. 6a,d). These results indicate that redox stress
induced by FH loss is, at least in part, responsible for the ensuing
senescence.
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Figure 5 | GSH succination triggers cystine uptake and GSH biosynthesis. (a–c) The loss of FH leads to the upregulation of the cystine transporter (a),
increased cystine uptake (b) and accelerated GSH biosynthesis traced from 13C5-glutamine (c). (d) The steady-state pool of GSH is increased in FH-
deﬁcient cells. (e,f,g) Sulfasalazin (SSZ) inhibits GSH biosynthesis in both wt and FH-deﬁcient cells (e) but selectively impairs cell survival and growth of
FH-deﬁcient cells (f,g). (h,i) 6-Aminonicotinamide (6-AN), an inhibitor of the PPP, inhibits pentose phosphate production in both cell lines as assessed by
tracing 13C6-Glucose (h), selectively affects the proliferation of FH-deﬁcient cells (i). The images in f are the representative images of triplicate cultures.
Results were obtained from three independent experiments and represented as average±s.e.m.
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We then wanted to test the direct role of GSH succination in
fumarate-induced senescence. Primary kidney cells and IMR90
cells were treated with DMF, a potent inducer of succination-
dependent oxidative stress and their proliferation was assessed.
DMF elicited a dose-dependent inhibition of cell proliferation
and induced SA-b-gal activity in non-transformed primary
mouse kidney epithelial cells (Fig. 6d and Supplementary
Fig. 5a,c). Consistent with these results, DMF-treated IMR90
exhibited profound proliferation defects (Fig. 6e and
Supplementary Fig. 5d), p21 upregulation (Fig. 6f) and SA-b-
gal positivity (Supplementary Fig. 5d), which were rescued by the
incubation with the antioxidant N-acetyl cysteine (Fig. 6e,f and
Supplementary Fig. 5d,e). These results strongly suggest that
fumarate-induced oxidative stress is sufﬁcient for the induction of
p21 and the initiation of cell senescence, regardless of cells’
genotype.
Fumarate-induced senescence in renal cysts of Fh1D/D mice.
Previous work demonstrated that the loss of FH in murine kid-
neys does not result in overt renal carcinomas, as observed in
HLRCC patients, but rather in benign cysts19. Our results
indicated that the redox stress mediated by the accumulation of
fumarate caused by the loss of Fh1 leads to senescence. Therefore,
we hypothesized that senescence could be a major adjournment
event of the tumorigenic process in Fh1-deﬁcient animals. To
test this hypothesis, we used the previously characterized
Fh1ﬂ/ﬂAhCre mice, which develop FH-deﬁcient renal cysts15.
Metabolite extraction conﬁrmed the presence of high levels of
succinicGSH in the kidneys of these animals (Fig. 7a). In line with
our ﬁndings in FH-deﬁcient cell lines, many of the epithelial cells
facing the lumen of the renal cysts showed an intense staining for
p21 (Fig. 7b). To address the role of p21 in the suppression of
tumorigenesis in Fh1-null mice, we crossed Fh1ﬂ/ﬂAhCre with
p21 / mice, obtaining animals deﬁcient for both Fh1 and p21
in the kidneys (Fh1D/Dp21 / ). Histological analyses revealed
that a simultaneous ablation of these genes resulted in the
presence of several hyperproliferative areas in the kidneys. This
was assessed by haematoxylin and eosin staining for cellular
density and by Ki67 for proliferative capacity of the cells20.
Strikingly, several areas of the kidneys of Fh1D/Dp21 / animals
were characterized by strong Ki67 staining (Fig. 7c þþ ;
quantiﬁed in Fig. 7d). In fact, 14 out of 24 (58.33%) of the
Fh1D/Dp21 / animals exhibited dense areas with proliferative
and locally invasive kidney epithelial cells (cytokeratin positive)
(Fig. 7c þþ and Supplementary Fig. 6). These results strongly
suggest that the bypass of senescence may initiate a tumorigenic
programme in Fh1-deﬁcient mice.
Discussion
FH is emerging as an important mitochondrial tumour
suppressor in both hereditary and sporadic forms of cancer2.
Although FH mutations in HLRCC were discovered more than a
decade ago, the speciﬁc consequences of the loss of this TCA cycle
enzyme remained unclear. The biochemical consequences of Fh1
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inactivation in both human and mouse cells have been extensively
investigated, revealing a complex pattern of metabolic defects,
including deregulation of TCA and urea cycle15. Nevertheless, a
global analysis of the metabolic rewiring on the loss of Fh1
is still missing. To address this question, we generated in silico
models to explore the metabolic consequences of FH inactivation.
These models, which integrate transcriptomics and consumption-
release metabolomics data to predict metabolic ﬂuxes, revealed
unexpected metabolic features of FH-deﬁcient cells. Interestingly,
we found that a large number of metabolic pathways became
essential on the loss of FH, among which haem biosynthesis and
degradation pathway and GSH biosynthesis were the most
enriched. While the haem biosynthesis and degradation
pathway has already been demonstrated to be synthetic lethal
in FH-deﬁcient cells, the role of GSH metabolism in FH-deﬁcient
cells has not been investigated before and required further
investigation. An untargeted intracellular metabolomics analysis
helped to shed light on these ﬁndings. We found that the aberrant
accumulation of fumarate leads to the persistent depletion of
GSH via the formation of the adduct succinicGSH. We conﬁrmed
that succinicGSH, which is all but absent from normal cells,
accumulates in both human and mouse FH-deﬁcient cells and in
the kidneys of Fh1-deﬁcient animals, suggesting that this
metabolite could be used as a beacon for toxic accumulation of
fumarate. In the work presented here, we showed that
succinicGSH is formed by a non-enzymatic reaction between
fumarate and the thiol residue of de novo biosynthesised GSH.
Furthermore, we found that succinicGSH is secreted by FH-
deﬁcient cells and can be degraded, in a process similar to GSH
catabolism, into succinic cys–gly.
SuccinicGSH has been recently identiﬁed in the human
FH-deﬁcient cancer cell line UOK262 (ref. 10). In this work,
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Sullivan et al.10 proposed that the detoxiﬁcation of succinicGSH
mediated by GR explains the enhanced oxidative stress in FH-
deﬁcient cells . However, our data showed that the contribution of
GR to succinicGSH degradation is minor and unlikely to account
for increased oxidative stress in these cells. Instead, we found that
succination of GSH signiﬁcantly increases the demands of
NADPH to sustain GSH biosynthesis from cysteine. This
reaction negatively affects redox homeostasis and, as a
compensatory mechanism, FH-deﬁcient cells enhance cystine
uptake and GSH biosynthesis. Therefore, although FH-deﬁcient
cells experience a chronic oxidative stress, GSH levels are not
compromised in these cells. How these cells genetically
orchestrate this metabolic reprogramming is not known. The
accumulation of fumarate in FH-deﬁcient human cancers has
been previously linked with the activation of the transcription
factor Nrf2 (refs 5,7), which elicits an antioxidant response and
prevents the elevation of ROS to toxic levels in these cells. Keap1
is also regulated by oxidation of its thiol residues21; therefore, the
increased oxidative stress observed in FH-deﬁcient cells could
also contribute to Nrf2 activation. We hypothesize that both the
redox stress caused by GSH succination and Keap1 succination
contribute to the emergence of the antioxidant signature and Nrf2
activation to support GSH biosynthesis and to maintain a viable
level of oxidative stress.
Persistent oxidative stress has been previously linked to the
induction of senescence18. We reasoned that overt oxidative stress
caused by the loss of FH in non-transformed cells could instigate
a tumour suppressive mechanism that could explain why Fh1-
deﬁcient animals do not develop carcinomas but only benign
cysts19. To accurately dissect the effects of accumulation of
fumarate in early phases of epithelial transformation, we silenced
FH in non-immortalized non-transformed cells. In primary
epithelial kidney cells and in human diploid ﬁbroblasts, the loss of
FH or incubation with DMF leads to a robust induction of
senescence, conﬁrmed by proliferative arrest, p21 upregulation
and SA-b-galactosidase activity. The incubation with antioxidants
abrogated the anti-proliferative response, suggesting that the
oxidative stress induced by fumarate accumulation is responsible
for the induction of senescence. In line with these results, we
observed that some renal cysts exhibit a strong positive staining
for p21, indicating that senescence is also a factor that may
prevent or delay malignant transformation in vivo. In line with
this notion, the co-ablation of p21 and Fh1 resulted in high
proportion of hyperprolifearative areas in the kidney.
Importantly, p21, but not p16 induction is also observed in
human HLRCC patients (Supplementary Fig. 4). These results
conﬁrm the association between FH loss and p21 induction in
human tumours. Furthermore, they may indicate that in human
FH-deﬁcient renal cancer, the lack of p16 induction may help
avoiding the senescence phenotype.
The observation that the loss of FH, a bona ﬁde tumour
suppressor gene22, could lead to senescence, although
counterintuitive, suggests that the role of FH in tumorigenesis
is complex and might involve secondary oncogenic alterations to
overcome senescence. It is worth mentioning that the loss of FH
is not the only example of an oncogenic event that leads to
senescence at early stages of tumorigenesis. Other examples
include the loss of the tumour suppressors VHL and PTEN23,24 as
well as the activation of the oncogenes Ras or BRAF25–27.
Although the underlying mechanisms that lead to senescence
within these models might be different, a general accepted
paradigm is that the unrestrained proliferation elicited by an
oncogenic event leads to the activation of tumour restraining
events. In this work we demonstrated that in the case of FH loss,
this activity is mediated by fumarate, at least in part via GSH
succination.
Methods
Animal work. Animal work was carried out with ethical approval from University
of Glasgow under the Animal (Scientiﬁc Procedures) Act 1986 and the EU
Directive 2010 (PPL 60/4181). Animals were housed in individual ventilated cages
in a barrier facility proactive in environmental enrichment. AhCre and p21 /
(Cdkn1atm1Led) mice were sourced from Owen Sansom (Cancer Research UK,
Beatson Institute, Glasgow)28,29, Fhﬂ/ﬂ mice kindly provided by Iain Tomlinson
(University of Oxford)19 and all were maintained on a C57Bl6 background.
Experimental mice (mixed sex) were aged to 12–18 months and no difference
between male and female animals was observed.
Cell culture. Fh1ﬂ/ﬂ, Fh1D/D, UOK262 and UOK262pFH cell lines were obtained
and cultured as previously described8. In brief, all cell lines were cultured in
DMEM supplemented with 10% fetal bovine serum and 2mM glutamine. The
mouse cell lines were also supplemented with 1mM pyruvate and 50 mgml 1
uridine.
Immunohistochemistry. Mouse kidneys were ﬁxed in 10% neutral buffered for-
malin and parafﬁn embedded. Sections (4 mm) were cut and stained for Ki67 (1:100
Thermo RM-9106), Cytokeratin (Cytokeratin, Pan Ab-1, Mouse Monoclonal
Antibody 1:100, Thermo, MS-34) and p21 (1:500 Santa Cruz, sc471).
Chemical reagents. Unless otherwise stated, all chemical compounds were pur-
chased form Sigma (Gillingham, Dorset, UK). 13C-labelled compounds were
purchased by Cambridge Isotopoes (Tewksbury, MA).
The transcriptomics signature of FH-deﬁcient cells. To examine whether the
Fh1D/D cells are under oxidative stress based on their gene expression (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63438) we identiﬁed genes whose
expression is signiﬁcantly higher in the Fh1D/D cells compared with the Fh1ﬂ/ﬂ cells
(false discovery rate-corrected P-valueso0.05) (ref. 8). We then assembled a set of
281 genes that are known to be involved in the response to oxidative stress. This set
includes genes that are annotated with one of the 32 gene ontology terms which are
child terms of the gene ontology term response to oxidative stress30 (for example,
response to ROS, response to superoxide, response to oxygen radical). We examined
if the genes that are signiﬁcantly upregulated in the Fh1D/D cells compared with the
Fh1ﬂ/ﬂ cells are enriched with this set of oxidative stress genes, via a hypergeometric
enrichment test. We then examined if FH deﬁciency induces a gene expression
signature of oxidative stress also in clinical samples. To this end, we analysed a
previously deﬁned set of 1,397 genes that are upregulated in HLRCC relative to
normal kidney tissues7, and tested if this set is enriched with oxidative stress genes
by performing a hypergeometric enrichment test.
Metabolomic extraction of mouse tissue. Kidneys were excised and immediately
processed for metabolomics extraction. Equal amounts of renal tissue were lysed in
250 ml of extraction solution per each 10mg of tissue in Precellysis vials following
manufacturer’s instruction. The extraction solution contained 30% acetonitrile,
50% methanol and 20% water. The suspension thus generated was immediately
centrifuged at 16,000 g for 15min at 0 C. The supernatant was then submitted to
LC-MS metabolomic analysis.
Metabolomic extraction of cell lines. Cells (5 105) were plated onto six-well
plates and cultured in standard medium for 24 h. For the intracellular metabolomic
analysis, cells were quickly washed for three times with PBS to remove con-
taminations from the media. The PBS was thoroughly aspirated and cells were
lysed by adding a precooled ES. The cell number was counted in a parallel control
dish, and cells were lysed in 1ml of ES per 1 106 cells. The cell lysates were
vortexed for 5min at 4 C and immediately centrifuged at 16,000g for 15min at
0 C. The supernatants were collected and analysed by LC-MS. For the metabo-
lomic extraction of spent media, 50 ml of cell media were deproteinized by 1:16
dilution in a solution composed of 80% acetonitrile and 20% water. The super-
natants were then processed as described above. Fresh medium without cells was
incubated in the same experimental conditions and used as a reference.
LC-MS metabolomic analysis. For the LC separation, column A was the Sequant
Zic-Hilic (150mm 4.6mm, internal diameter (i.d.) 5 mm) with a guard column
(20mm 2.1mm i.d. 5 mm) from HiChrom, Reading, UK. Mobile phase A: 0.1%
formic acid v/v in water. Mobile B: 0.1% formic acid v/v in acetonitrile. The ﬂow
rate was kept at 300 ml min 1 and gradient was as follows: 0min 80% of B, 12min
50% of B, 26min 50% of B, 28min 20% of B, 36min 20% of B, 37–45min 80% of B.
Column B was the sequant Zic-pHilic (150mm 2.1mm i.d. 5 mm) with the guard
column (20mm 2.1mm i.d. 5 mm) from HiChrom, Reading, UK. Mobile phase
C: 20mM ammonium carbonate plus 0.1% ammonia hydroxide in water. Mobile
phase D: acetonitrile. The ﬂow rate was kept at 100ml min 1 and gradient as
follow: 0min 80% of D, 30min 20% of D, 31min 80% of D, 45min 80% of D.
The mass spectrometer (Thermo Exactive Orbitrap) was operated in a polarity
switching mode.
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13C-glutamine and cystine labelling experiments. Cells (5 105) were plated
onto six-well plates and cultured in standard medium for 12 h. The medium was
then replaced by fresh medium supplemented with either 2mM U-13C-Glutamine
or 0.2mM 13C2-Cystine for the indicated time.
Orbitrap-Velos MS2 fragmentation. The S-(1, 2-Dicarboxyethyl) GSH standard
(H-1556.1000, Bachem) was dissolved in water and diluted to 40 mgml 1 with a
50% mixture of acetonitrile and water. An Orbitrap-Velos mass spectrometer was
used in the negative mode, with HCD fragmentation MS2 energy of 50 unit.
NMR measurement. Proton and two-dimensional pfgCOSY as well as pfgTOCSY
were measured for standards and samples on an ECX 400 Jeol NMR equipped with
a pulse-ﬁeld gradient autotune 40TH5AT/FG broadband high-sensitivity probe. 1H
NMR (400MHz, Methanol-d4) d 3.98 (s, 2H), 3.85–3.71 (m, 2H), 3.38 (s, 1H), 2.97
(dq, J¼ 18.1, 9.3Hz, 3H), 2.75 (dd, J¼ 17.1, 5.9Hz, 3H), 2.72–2.58 (m, 1H), 2.22
(m, 1H).
Bioinformatics processing and statistical analysis of the metabolomic data.
The metabolomics analyses obtained from cells and media extractions were log2
transformed and the replicates normalized using quantile normalization. Then, a
multi-factor analysis of variance and multiple test correction were used to identify
metabolites signiﬁcantly different between experimental groups. Analyses were
performed using Partek Genomics Suite Software, version 6.5 Copyright 2010 and
R version 2.14.0.
In vitro succination reaction. GSH (2mM) and 8mM 13C2-fumarate were mixed
in 2ml of a solution composed of 50mM NaCl, 20mM Tris and 0.1% Triton-X-
100, pH¼ 7.4, 4 C for 8 h in the presence or absence of cell lysate obtained from
2 106 Fh1D/D cells previously heat inactivated (100 C for 1 h) or left untreated.
Protease inhibitor cocktail (Sigma) was used following manufacturer’s instructions.
At the end of the experiment, the mixture was quenched using the extraction
solution for metabolomics (see above) and the extracts were spun down at max-
imum speed for 10min. The supernatant was subsequently analysed by LC-MS.
DMF treatment. Cells (5 105) were plated onto six-well plates and cultured in
standard medium for 24 h. Then the cell culture medium was replaced with
medium supplemented with the indicated concentrations of DMF for the indicated
time. Cells were then harvested and extracted as described above.
GSH GR assay. SuccinicGSH (0.2mM, purchased from BACHEM) and GSSG
(2mM) were separately dissolved in a solution containing 50mM Tris and 5mM
EDTA. The pH was adjusted at 7.8 to mimic the pH of the mitochondrial matrix.
Substrates were added to a solution of 250 mM NADPH and 0.05Uml 1 GSH GR.
Metabolite production was monitored by LC-MS.
qPCR experiments. mRNA was extracted as previously described8. In brief, RNA
was extracted from cells of the indicated genotype using the Qiagen RNAeasy RNA
extraction kit (Qiagen, Manchester, UK) following the manufacturer’s
instructions.mRNA (1 mg) was retrotranscribed into cDNA using High Capacity
RNA-to-cDNA kit (Life Technologies, Paisley, UK). qPCR reaction was performed
using 200 ng of cDNA, the indicated primers and fast Sybr green mastermix (Life
Technologies). Primers were designed using ROCHE universal probe library
primer design tool (version 2.45 and 2.48) and the sequences were as follow:
p21 FW: 50-GAGGGCTAAGGCCGAAGATG-30 , RV: 50-GCAGACCAGCCTG
ACAGATTTC-30
Rpl34 FW: 50-GTGAGGGACGAGGAGAGGTG-30 , RV: 50-ACCATCCTGAG
TGCCGCTTC-30
Slc7a11 FW: 50-TGGGTGGAACTGCTCGTAAT-30 , RV: 50-AGGATGTAGCG
TCCAAATGC-30
DDIT3 FW: 5-GCGACAGAGCCAGAATAACA-30 , RV 50-GATGCACTTCCT
TCTGGAACA-30
PTGS1 FV: 50-CCTCTTTCCAGGAGCTCACA-30 , RV: 50-TCGATGTCACCG
TACAGCTC-30
PYCR1 FW: 50-CTGACCATGTCAAGCCACTG-30 , RV 50-TTCCCAGGGATA
GCTGAGGT-30
NQO1 FW: 50- AGCGTTCGGTATTACGATCC-30, RV: 50- AGTACAATCAG
GGCTCTTCTCG-30
ABCB1A FW: 50-GGGCATTTACTTCAAACTTGTCA-30 , RV: 50-TTTACAA
GCTTCATTTCCTAATTCAA-30
GCLC FW: 50-ATGATAGAACACGGGAGGAGAG-30 , RV: 50-TGATCCTAA
AGCGATTGTTCTTC-30
HMOX1 FW: 50-gtcaagcacagggtgacaga-30 RV 50-atcacctgcagctcctcaaa-30
For the qPCR reactions, 0.5 mM primers were used—1 ml of Fast Sybr green gene
expression master mix; 1 ml of each primers and a 4 ml of a 1:10 dilution of cDNA in
a ﬁnal volume of 20 ml were used. Real-time PCR was performed in the 7500 Fast
Real-Time PCR System (Life Technologies) using the fast Sybrgreen programme
and expression levels of the indicated genes were calculated using the DDCt
method by the appropriate function of the software using actin as calibrator.
Primary kidney cells isolation and infection. Primary kidney epithelial cells were
isolated from Fh1þ /þ and Fh1ﬂ/ﬂ p5 mice as described previously31 and cultured
in DMEM supplemented with 10% fetal bovine serum, 2mM glutamine and
1mmol l 1 pyruvate. Cells were infected with Cre recombinase-encoding
adenovirus (Ad5-CMV-Cre-GFP, Vector Development Laboratory) using 200 p.f.u.
per cell. After 2 days, cells were transferred on 24-well plates for growth curve
determination and SA-b-Gal Staining.
Lentiviral infection of IMR90. The viral supernatant for infection was obtained
from the ﬁltered growth media of the packaging cells HEK293T transfected with
3 mg psPAX, 1 mg pVSVG, 4 mg of short hairpin RNA (shRNA) constructs and 24 ml
of Lipofectamine 2000 (Life Technology). Cells (3 105) were then plated on six-
well plates and infected with the viral supernatant in the presence of 4 mgml 1
polybrene. After two days, the medium was replaced with selection medium
containing 1 mg ml 1 puromycin. The expression of the shRNA constructs was
induced by incubating cells with 2 mgml 1 doxycyclin. The shRNA sequences
were purchased from Thermoscientiﬁc (NTC: # RHS4743; sh #2 V3THS_324847
and sh#3: V3THS_324846)
Senescence-associated (SA)-b-Gal staining. For mouse epithelial kidney cells,
4 104 cells were treated for 2 days with 50 mM DMF and a Senescence b-
Galactosidase Staining Kit (Cell Signaling Technology) was used. The staining was
performed according to manufacturer’s instructions and images were acquired with
a Zeiss Axiovert 200M microscope. To quantify SA-b-gal positive cells, cells were
counted in four random ﬁelds in each of the triplicates wells.
For IMR90, 4 104 cells were plated onto coverslips in a 24-well plate. The day
after the medium was replaced with medium containing either DMF or N-acetyl
cysteine or a combination of the two drugs. The medium was replenished every day
for a total of 5 days of treatment. At the end of the experiment, cells were washed in
PBS and ﬁxed with 0.5% glutaraldehyde solution (in PBS) for 15min at room
temperature. Immediately after cells were washed twice with 1mM MgCl2 in
PBS (pH 6.0) and incubated with a staining solution composed of 1mgml 1
5-Bromo-4-chloro-3-indolyl-b-D-galactopyranoside (prepared in N,N-dimethyl-
formamide), 0.12mM K3Fe(CN)6, 0.12mM K4Fe(CN)6 and 1mM MgCl2/PBS
(pH 6.0) at 37 C overnight in CO2-free incubator. The day after, cells were washed
three times with deionized water and imaged with a Zeiss Axiovert 40 CFL
microscope using a  10 objective.
Cell proliferation. IMR90 (4 104) were plated in a 24-well plate and placed onto
the stage of the Incucyte Live Content Imaging instrument. Nine ﬁelds for each
well were collected every 2 hours for the ﬁrst day and then every hour for the
following days. Cell proliferation was automatically determined from bright-ﬁeld
images by calculating cell conﬂuence at different time points, using the appropriate
function of the Incucyte software. Cell media was replaced daily with media sup-
plemented with the indicated drugs.
Generation of the metabolic models of Fh1D/D and Fh1ﬂ/ﬂ cells. To investigate
the metabolic changes that occur due to FH-inactivation metabolic models of Fh1D/
D and Fh1ﬂ/ﬂ, cell lines were constructed based on their transcriptomics and
uptake-secretion metabolomics. The construction was conducted in two stages. In
the ﬁrst stage, each model was constrained to obtain an optimal ﬁt to the gene
expression signature of the cell line by solving a Mixed Integer Linear Program-
ming problem, via the integrative Metabolic Analysis Tool (iMAT)32,33. In the
second stage, each model was further constrained to obtain an optimal ﬁt to the
measured uptake-secretion ﬂux rates. The latter was achieved by forming the
following problem:
min
X
i2Rflux
yi ð1Þ
subject to
S  v ¼ 0 ð2Þ
8i : vi;min  vi  vi;max ð3Þ
8i 2 Rm : vi  fij j  yi ð4Þ
Where v is the ﬂux vector and S is an m n stoichiometric matrix, in which m is
the number of metabolites and n is the number of reactions. The mass balance
constraint is enforced by equation (2). Thermodynamic and enzyme capacity
constraints are imposed in equation (3), by setting vi,min and vi,max as a lower and
upper bound of the ﬂux values through reaction i, respectively. In equation (4), Rm
includes the set of measured reactions; for each measured reaction i, the variables yi
represents the deviation of its computed ﬂux rate, denoted as vi, from its measured
ﬂux rate, denoted as fi. The objective function equation (1) is to minimize the
deviation of the computational ﬂux rates from the measured ﬂux rates. To avoid
the non-linear constraint imposed in equation (4) two variables, yþ and y , are
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introduced to convert the problem to its equivalent linear form.
min
X
i2Rflux
ðyþi þ yi Þ ð1Þ
subject to
S  v ¼ 0 ð2Þ
8i : vi;min  vi  vi;max ð3Þ
8i 2 Rm :  yi  vi  fi  yþi ð4Þ
0  yþi ; yi ð5Þ
A solution found by the Mixed Integer Linear Programming solver to the iMAT
problem and then by a Linear Programming solver to the problem formulated
above is guaranteed to be optimal, meaning, to maximize the similarity to the
expression and then, under the optimal ﬁt to the transcriptomics to obtain a
maximal ﬁt to the ﬂux measurements. However, the solution is not necessarily
unique, as a space of alternative optimal solutions may exist. The space of optimal
solutions represents various steady-state ﬂux distributions attaining the same
similarity with the expression data and ﬂux measurements. To account for these
alternative solutions, the optimal similarity to the expression and ﬂux
measurements is calculated. The model is then constrained to attain this optimal
similarity, which reduces the solution space signiﬁcantly.
To explore the optimal solution space of the model, that is, the feasible
metabolic states which maximize the ﬁt to the experimental data, ﬂux variability
analysis (FVA)34 was employed. FVA obtains for each reaction its minimal and
maximal attainable ﬂux, subject to the aforementioned constraints. In addition, by
applying FVA, the maximal production rate of every metabolite in the models was
computed; in this case, the production of a metabolite was deﬁned as the sum of its
production rates in all the different compartments of the model (for example,
mitochondria, cytoplasm). For each metabolic pathway, the median fold-change in
the production of its metabolites was computed based on the pathway deﬁnition of
ref. 13. Fianlly, the redox potential of the models was estimated by computing their
capacity to produce NADH and NADPH from NADþ NADPþ , respectively.
The metabolic model of the FH-deﬁcient cells were utilized to examine the
dependency of GSH production on the uptake-secretion rates of different
metabolites, including amino acids and main carbon sources. First, for each
metabolite in this set, the feasible ﬂux range of its exchange reaction was computed
via FVA. An exchange reaction represents the secretion or uptake of a given
metabolite. A positive ﬂux rate through an exchange reaction denotes secretion and
a negative ﬂux rate denotes uptake. Next, for every one of the metabolites the
model was constrained to carry out an increasing ﬂux of its exchange reaction,
which is within its feasible ﬂux range. Under each of these constraints, the maximal
production of reduced GSH in the model was computed. Finally, for each
metabolite, the Spearman correlation between the upper bounds of the metabolite
exchange reaction and the pertaining maximal production rates of GSH was
computed. A positive correlation, as found between GSH production and arginine,
denotes that a higher ﬂux rate through the exchange reaction of the metabolite—
less uptake or more secretion—enables the model to produce GSH more rapidly.
Likewise, a negative correlation, as found between GSH production and cystine,
denotes that a lower ﬂux rate through the exchange reaction of the metabolite—
more uptake or less secretion—enables the model to produce GSH more rapidly.
The ability of the models to predict the measured ﬂux rates was examined in a
leave-one-out cross-validation process. Every iteration, the models were
regenerated based on their gene expression and a partial set of the metabolic uptake
and secretion rates. These models were then used to compute via FVA the maximal
and minimal ﬂux rate of the exchange reaction whose ﬂux measurement was
omitted from the construction process. Signiﬁcant correlation was found between
the measured and predicted ﬂux rates (Supplementary Table 2).
Following the validation of the models, they were utilized to systematically
explore the metabolic differences between the Fh1D/D and Fh1ﬂ/ﬂ cells. The capacity
of the two models to produce each of their 1,491 metabolites was computed. The
FH-deﬁcient model was found to have a higher capacity to produce 43 metabolites
(Supplementary Fig. 1b). Among the top ones are four derivatives of GSH:
Oxidized GSH, reduced GSH, (R)-S-Lactoylgutathione and S-Formylglutathione
(Supplementary Fig. 1b). These results suggest that FH deﬁciency induces oxidative
stress. To further examine this hypothesis, the ability of the Fh1ﬂ/ﬂ and Fh1D/D
models to produce reducing power in the form of NADH and NADPH was
computed. Indeed, the Fh1ﬂ/ﬂ model was found to have a signiﬁcantly higher
capacity to produce NADH and NADPH, compared with the Fh1D/D model.
Following the discovery of GSH succination in the FH-deﬁcient cells, the
models were reconstructed with GSH succination (see next section). According to
the updated models, GSH succination further severely limits NADPH and NADH
production in Fh1D/D cells. This strong coupling between GSH succination and
decreased NADH/NADPH production is highly notable, since the activity of
almost all other reactions in the Fh1D/D model does not entail such a decrease
(Supplementary Fig. 1c, Wilcoxon ranksum P value of 7.91e 04). Further
computational analysis revealed that this coupling arises since, in the Fh1D/D cells,
GSH synthesis depends on cystine uptake, rather than on methionine uptake
(Supplementary Fig. 3b). The synthesis of GSH from cystine causes the oxidation of
two GSH molecules. As reducing them requires NADPH, it imposes a constraint to
activate pathways that contribute to NADPH production.
GSH succination was introduced to the models by adding the following
reactions
(1) Mitochondrial reaction: reduced GSH [m]þ fumarate [m]-succinicGSH
(2) Cytoplasmatic reaction: reduced GSH [c]þ fumarate [c]-succinicGSH
(3) Sink reaction: succinicGSH
Reaction (3) denotes the secretion of succinicGSH. In the FH-deﬁcient model,
this reaction was constrained to carry a non-zero ﬂux. Note that some of the
succinicGSH may be metabolized via additional metabolic reactions which are yet
to be discovered, as opposed to secreted. However, currently, the models cannot
account for such reactions.
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